NEW YORK – Predictive Oncology subsidiary Helomics has signed a pair of agreements to use its artificial intelligence-based platform in oncology decision making.
First, Helomics said today that it is partnering with the University of Pittsburgh Medical Center to use AI to potentially improve clinical decision making for ovarian cancer patients. In addition, Interpace Diagnostics said that it is working with Helomics to develop tools that diagnose and assess the risk of thyroid cancer.
Helomics and UPMC are specifically using Helomics' AI-based D-CHIP (Dynamic Clinical Health Insights Platform) to analyze the genomic and drug response profiles of ovarian cancer individuals to find predictive value in terms of response or non-response to therapy. The group believes the partnership will highlight the potential of using AI-powered, evidence-based decision making to predict clinical outcomes in ovarian cancer patients.
"We believe that by linking both the drug response profile and the genomic profile of the patient's tumor using a machine learning approach, we can provide 'multi-omic' predictive models that will have greater decision-making impact than just genomics alone, which in turn will positively benefit oncologists and their patients," Helomics Chief Innovation Officer Mark Collins said in a statement.
While financial details of the agreement were not fully disclosed, UPMC Enterprises will partly fund the project, Helomics said.
"We believe that this effort will enhance our understanding of the molecular profiles of women with ovarian cancer by using the power of AI to create predictive models of therapeutic success," University of Pittsburgh School of Medicine obstetrics, gynecology, and reproductive sciences professor Robert Edwards said in a statement.
Meanwhile, Helomics signed an agreement with Interpace Diagnostics to develop products that work together to diagnose and assess the risk for thyroid cancer. The tools will also provide appropriate therapeutic recommendations by integrating Interpace's ThyGeNEXT and ThyraMir assays with Helomics' D-CHIP tool.
As part of the collaboration, Helomics will build a model using Interpace's clinical data, which the group believes can be applied to find druggable targets for aggressive and indolent thyroid cancer treatment.
"We believe that this collaboration with Helomics is a significant step to help us better diagnose thyroid cancer, resulting in existing product line extensions as well as potentially new products and partnerships based on the AI-driven models Helomics is building," Interpace CEO Jack Stover said in a statement.
Financial details of the agreement were undisclosed.
Helomics previously partnered with molecular imaging firm ChemImage in June to develop technology for monitoring how prostate cancer responds to treatment.